Jim Simons Syndax Pharmaceuticals Inc Transaction History

Renaissance Technologies LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$18.82 - $23.79 $2.54 Million - $3.22 Million	135,200 Added 170.92%	214,300 $4.4 Million
Q1 2024 May 13, 2024	BUY	$19.71 - $24.57 $1.56 Million - $1.94 Million	79,100 New	79,100 $1.88 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $3.17 Million - $4.75 Million	218,300 New	218,300 $3.17 Million
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $1.68 Million - $2.13 Million	81,200 New	81,200 $2.07 Million
Q2 2022 Aug 12, 2022	SELL	$13.64 - $19.48 $2.48 Million - $3.55 Million	-182,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $2.7 Million - $4.03 Million	182,100 New	182,100 $3.17 Million
Q3 2020 Nov 13, 2020	SELL	$13.39 - $17.48 $1.27 Million - $1.66 Million	-94,700 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$8.94 - $20.98 $3.51 Million - $8.24 Million	-392,900 Reduced 80.58%	94,700 $1.4 Million
Q1 2020 May 14, 2020	SELL	$6.65 - $12.03 $52,535 - $95,037	-7,900 Reduced 1.59%	487,600 $5.35 Million
Q4 2019 Feb 13, 2020	SELL	$5.43 - $9.22 $8,145 - $13,830	-1,500 Reduced 0.3%	495,500 $4.35 Million
Q3 2019 Nov 13, 2019	BUY	$7.47 - $10.76 $486,297 - $700,476	65,100 Added 15.07%	497,000 $3.71 Million
Q2 2019 Aug 12, 2019	BUY	$4.9 - $9.31 $574,770 - $1.09 Million	117,300 Added 37.29%	431,900 $4.02 Million
Q1 2019 May 14, 2019	BUY	$4.26 - $6.86 $364,230 - $586,530	85,500 Added 37.32%	314,600 $1.65 Million
Q4 2018 Feb 13, 2019	BUY	$3.6 - $8.42 $824,760 - $1.93 Million	229,100 New	229,100 $1.02 Million

230

90M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.